{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:08Z","timestamp":1792787828375,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Practical Research Project for Rare\/Intractable Diseases of the Japan Agency for Medical Research and Development","id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan","id":[{"id":"https:\/\/ror.org\/03mwa7s65","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) can cause severe neurological disability after a single relapse. Although relapse rates have markedly decreased with the emergence of targeted biologics, treatment switches are increasingly encountered due to long-term treatment considerations and adverse events. However, safe switching strategies, especially within 12 months after a relapse, which we defined operationally as the \u201ccluster phase\u201d, have not been established. We investigated relapse risk and potential preventive strategies when switching from complement inhibitors in AQP4-IgG\u2013positive NMOSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed patients with AQP4-IgG\u2013positive NMOSD treated at St. Marianna University School of Medicine who underwent at least one biologic switch. Clinical records were assessed for patient characteristics, treatment history, timing of switching, and relapse occurrence. Particular attention was given to switching from complement inhibitors during the cluster phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 14 patients who switched biologics, 5 switched from complement inhibitors, 4 switched between complement inhibitors, 2 between B-cell\u2013depleting therapies, and 3 from IL-6 receptor inhibitors. Six of the 14 switches occurred during the cluster phase, including 3 from complement inhibitors (all to B-cell\u2013depleting agents). One of the two patients switched without bridging therapy during the cluster phase experienced optic neuritis relapse, while no relapses occurred in the other 13 switching cases. This observation suggests a possible vulnerability during the cluster phase, although definitive conclusions cannot be drawn due to the small sample size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching from complement inhibitors during the cluster phase may be associated with an increased susceptibility to relapse. Bridging strategies, such as plasma exchange or temporary biologic overlap, may help reduce the likelihood of therapeutic gaps, but these findings remain hypothesis-generating. Clinicians should proactively discuss future switching scenarios and develop long-term treatment plans with patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05130-x","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:11:03Z","timestamp":1782727863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching from complement inhibitors in AQP4-IgG\u2013positive NMOSD: clinical characteristics, an operational \u201ccluster phase\u201d and potential strategies to prevent therapeutic gaps"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-6753","authenticated-orcid":false,"given":"Kenzo","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kaburagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Isahaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanao","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"5130_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. https:\/\/doi.org\/10.1186\/1742-2094-9-14.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"5130_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett J, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368. https:\/\/doi.org\/10.1002\/ana.26626.","journal-title":"Ann Neurol"},{"issue":"6","key":"5130_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","volume":"23","author":"BA Cree","year":"2024","unstructured":"Cree BA, Kim HJ, Weinshenker BG, et al. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024;23(6):588\u2013602. https:\/\/doi.org\/10.1016\/S1474-4422(24)00077-2.","journal-title":"Lancet Neurol"},{"key":"5130_CR4","doi-asserted-by":"publisher","first-page":"105502","DOI":"10.1016\/j.msard.2024.105502","volume":"84","author":"I Nakashima","year":"2024","unstructured":"Nakashima I, Nakahara J, Yasunaga H, et al. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: results from a Japanese claims database. Mult Scler Relat Disord. 2024;84:105502. https:\/\/doi.org\/10.1016\/j.msard.2024.105502.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"5130_CR5","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1212\/NXI.0000000000000640","volume":"7","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Nakashima I, Takahashi T, et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. 2020;7(1):e640. https:\/\/doi.org\/10.1212\/NXI.0000000000000640.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"5130_CR6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale(EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology"},{"key":"5130_CR7","doi-asserted-by":"publisher","first-page":"104949","DOI":"10.1016\/j.msard.2023.104949","volume":"79","author":"S Sen","year":"2023","unstructured":"Sen S, Tuncer A, Terzi M, et al. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment. Mult Scler Relat Disord. 2023;79:104949. https:\/\/doi.org\/10.1016\/j.msard.2023.104949.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"5130_CR8","doi-asserted-by":"publisher","first-page":"e213399","DOI":"10.1212\/WNL.0000000000213399","volume":"104","author":"E Maillart","year":"2025","unstructured":"Maillart E, Dubessy AL, Shor N, et al. Severe relapse after switching from eculizumab to satralizumab in neuromyelitis optica spectrum disorder. Neurology. 2025;104(5):e213399. https:\/\/doi.org\/10.1212\/WNL.0000000000213399.","journal-title":"Neurology"},{"issue":"14","key":"5130_CR9","doi-asserted-by":"publisher","first-page":"e42067","DOI":"10.1097\/MD.0000000000042067","volume":"104","author":"D Li","year":"2025","unstructured":"Li D, Ye J, Hong Z, et al. Satralizumab after inebilizumab treatment in a patient with recurrent neuromyelitis optica spectrum disorder: a case report. Medicine (Baltimore). 2025;104(14):e42067. https:\/\/doi.org\/10.1097\/MD.0000000000042067.","journal-title":"Medicine (Baltimore)"},{"key":"5130_CR10","doi-asserted-by":"publisher","first-page":"578585","DOI":"10.1016\/j.jneuroim.2025.578585","volume":"403","author":"H Abboud","year":"2025","unstructured":"Abboud H, Steingo B, Vargas D, et al. Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: a case series. J Neuroimmunol. 2025;403:578585. https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578585.","journal-title":"J Neuroimmunol"},{"key":"5130_CR11","doi-asserted-by":"publisher","first-page":"103352","DOI":"10.1016\/j.msard.2021.103352","volume":"57","author":"EP Flanagan","year":"2022","unstructured":"Flanagan EP, Levy M, Katz E, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use: results from the N-MOmentum study. Mult Scler Relat Disord. 2022;57:103352. https:\/\/doi.org\/10.1016\/j.msard.2021.103352.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"5130_CR12","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(11):3072\u201380. https:\/\/doi.org\/10.1093\/brain\/awn240.","journal-title":"Brain"},{"issue":"4","key":"5130_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3988\/jcn.2021.17.4.599","volume":"17","author":"JM Seok","year":"2021","unstructured":"Seok JM, Park MS. Relapse after cessation of immunosuppressants in seropositive neuromyelitis optica spectrum disorder with long-term remission. J Clin Neurol. 2021;17(4):599\u2013601. https:\/\/doi.org\/10.3988\/jcn.2021.17.4.599.","journal-title":"J Clin Neurol"},{"issue":"10","key":"5130_CR14","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"issue":"5","key":"5130_CR15","doi-asserted-by":"publisher","first-page":"e84703","DOI":"10.7759\/cureus.84703","volume":"17","author":"R Amano","year":"2025","unstructured":"Amano R. Ravulizumab is effective and safe for neuromyelitis optica spectrum disorder patients in various clinical settings: a single-center case series with concomitant use of rituximab. Cureus. 2025;17(5):e84703. https:\/\/doi.org\/10.7759\/cureus.84703.","journal-title":"Cureus"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05130-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:35Z","timestamp":1789556615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05130-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5130"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05130-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9158568\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of St. Marianna University School of Medicine (Approval No. 6092). Written informed consent was obtained from all participants. This study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication was obtained from all patients.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"584"}}